Drug intelligence / Profile preview

lidocaine + mepivacaine

Development stage: Unknown
Modality: Small Molecules
Administration: Infiltration, Nerve Block, Epidural

Overview

A combination of two local anesthetics used primarily in dental procedures. The combination leverages the properties of both anesthetics to potentially improve efficacy and reduce injection pain. Often used in a specific sequence - 3% mepivacaine plain followed by 2% lidocaine with 1:100,000 epinephrine, particularly for inferior alveolar nerve blocks and in highly inflamed areas.

Brand names: LEEP REDIKIT

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine + mepivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + mepivacaine.

Explore the full profile